Get a Free Consultation
Coronavirus pandemic

Coronavirus and Guidance to Cancer Patients – Massive Bio

Dr. Arturo Loaiza-Bonilla, MD MSEd

“At this unprecedented time of uncertainty related to the COVID-19 pandemic, Massive Bio is committed to be part of the solution to cancer patients wishing to enroll in clinical trials. Working with regulatory agencies, pharmaceutical companies, CROs and research sites across the globe, we are using our Artificial Intelligence-based technologies (Deep Learning Tumor Board, Clinical Trial Matching System, GEO-MAP population finder, and SYNERGY-AI) to identify and overcome barriers for patients to enroll in novel studies that may improve their cancer outcomes, amid this global pandemic” said Massive Bio’s Co-founder and CMO, Dr. Arturo Loaiza-Bonilla.”

The novel Coronavirus that causes COVID-19 infection (named SARS-CoV-2 by the World Health Organization – WHO -) has resulted in a pandemic, and likely the most challenging global public health crisis in modern history, affecting hundreds of thousands of individuals worldwide, including tens of thousands of cases in the United States, and with the potential to infect individuals of all ages.

However, older individuals and patients with underlying health conditions, including cardiovascular disease, diabetes, and pulmonary disorders, seem to be most vulnerable to infection and to developing more severe illness. Patients with cancer must also be considered in this vulnerable and high-risk population, and are affected not only because of potential increased morbidity and mortality, but also because quarantines, health care access scarcity and other factors related to the pandemic may compromise patient’s treatments and cancer care overall, including clinical trials.

This global pandemic affects everyone, and the FDA has recognized that the COVID-19 pandemic may impact the conduct of clinical trials, including drugs, devices and biological products. Challenges may arise, for example, from quarantines, site closures, travel limitations, interruptions to the supply chain for the investigational product, or other considerations if site personnel or trial subjects become infected with SARS-CoV-2, the virus that causes COVID-19. These challenges may lead to difficulties in conducting the clinical trials. It is anticipated potential disruptions to adherence to visit schedules, protocol deviations, and access to hospitals and facilities, and that such issues may be different for every trial, site and patient. Amid this Coronavirus outbreak, the safety and well-being of all members of the research mission, site staff, our company’s staff and cancer patients is our highest priority.

At Massive Bio we are following closely the principles of recently issued FDA guidance , which allows some flexibility approaches during these times. At the highest level, assuring safety of trial participants, maintaining compliance with GCP principles and minimizing risks to trial integrity, are key to our mission.

On our end, we are working diligently with patients, our business partners, and other key members of the research ecosystem to ensure continued accrual to clinical trials, using a patient-centric and data-driven approach, aimed to reducing the burden on sites and sponsors, and helping to advance cancer research at this time of major need for global collaboration, more than ever.

For other resources and information about COVID-19:


  • Marc says:

    Are you running clinical trials? I am a prostate cancer patient. My doc told I could join clinical trials by New York is shut down by the president. Can I join a clinical trial in other states? What shall I do?

  • Editor says:

    Thank you for your message Marc. We understand that dealing with cancer treatment while we face this pandemic can be difficult and scary. If you and your oncologist are in agreement, Massive Bio can assist in finding a clinical trial in which you could potentially be eligible for outside of New York. While there may be some barriers due to the pandemic, Massive Bio will work to overcome those obstacles and find the best options and quickest turnaround time for enrolling to a trial.

  • Francis says:

    Everything is very open and very clear explanation of issues was truly information. Your website is very useful. Thanks for sharing.

    • Fiona Evans says:

      Massive Bio is committed to helping patient’s overcome this crisis, and are happy you found this information clear and informative!

Leave a Reply

Your email address will not be published. Required fields are marked *

Join our community
and receive our newsletter